Amgen’s Stelara Biosimilar Produces Positive Phase III Results
Firm’s ABP 654 Ustekinumab Candidate Is Also Being Lined Up For Interchangeability
Executive Summary
Amgen has reported positive preliminary results from a Phase III study for its ABP 654 proposed ustekinumab biosimilar rival to Stelara, for which the firm also intends to pursue an interchangeability designation.
You may also be interested in...
Amgen Sued On US Stelara Biosimilar After Providing May 2023 Intent
With Janssen’s Stelara set to lose its exclusivity in September 2023, the originator is looking to ward off potential biosimilar competition from Amgen by suing the firm for patent infringement in a US district court.
Hikma Taps Celltrion Again To Bring In MENA Stelara Biosimilar
Hikma has signed another partnership agreement to gain Middle East and North Africa commercialization rights to an ustekinumab biosimilar – although not with its US partner, Bio-Thera Solutions.
As Biosimilar Revenues Fall, Amgen Looks To Next Wave For Growth
With previously leading Amgen biosimilars such as Mvasi (bevacizumab) and Kanjinti (trastuzumab) seeing their sales decline, the firm is turning its attention to the next wave of biosimilars that will drive future growth.